{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:30:56Z","timestamp":1789475456390,"version":"build-2803163510"},"reference-count":56,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Xi\u2019an Medical Research-Discipline Capacity Building project","award":["23YXYJ0002"],"award-info":[{"award-number":["23YXYJ0002"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,2,6]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"\n Objective<\/jats:title>\n To compare the efficacy and safety of different anti-vascular endothelial growth factor (VEGF) agents combined with different delivery methods for neovascular glaucoma (NVG).<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Systematic review and Bayesian network meta-analysis (NMA).<\/jats:p>\n <\/jats:sec>\n \n Data sources<\/jats:title>\n PubMed, Embase, Cochrane Library, Web of Science, ClinicalTrials.gov, ISRCTN and Chinese databases including the China National Knowledge Infrastructure, China Science Periodical Database (Wanfang Database), VIP Journal Integration Platform and China Biology Medicine Database were searched from inception to 5 September 2022.<\/jats:p>\n <\/jats:sec>\n \n Eligibility criteria<\/jats:title>\n We included randomised controlled trials (RCTs) that investigated the treatment of NVG using different anti-VEGF agents combined with various methods of drug administration, without any language limitations. All patients included underwent panretinal laser photocoagulation and there were no restrictions on prior glaucoma surgery.<\/jats:p>\n <\/jats:sec>\n \n Data extraction and synthesis<\/jats:title>\n Two independent reviewers extracted data and assessed the risk of bias. Random-effect Bayesian NMA was conducted to compare the efficacy and safety and rank priority of anti-VEGF regimens. The source of heterogeneity and the related factors affecting the stability of the results were also explored. CINeMA (Confidence in Network Meta-Analysis) was used to assess the certainty of evidence.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Our analysis included 17 RCTs involving a total of 1311 eyes from 1228 patients. We examined five different treatment regimens, which used three different anti-VEGF drugs. The following treatments showed a significant decrease in intraocular pressure (IOP) compared with the control group at 1\u2009month after glaucoma surgery: simultaneous intravitreal and intracameral injection of conbercept (ICCIVC) (mean difference (MD)=\u221211.56, 95% credible interval (CrI) \u221220.8 to \u22122.24), intravitreal injection of conbercept (MD=\u22128.88, 95% CrI \u221213.93 to \u22123.78), intravitreal injection of ranibizumab (MD=\u22127.62, 95% CrI \u221210.91 to \u22124.33) and intravitreal injection of bevacizumab IVB) (MD=\u22125.51, 95% CrI \u221210.79 to \u22120.35). The surface under the cumulative ranking curve (SUCRA) analysis indicated that ICCIVC (82.0%) may be the most effective regimen in reducing IOP. In terms of safety, there were no statistically significant differences among the interventions. According to the SUCRA analysis, ICCIVC (68.0%) was considered the safest choice with the fewest complications. Subgroup and meta-regression analyses showed that mean age was the main source of heterogeneity. Sensitivity analysis demonstrated the robustness of the study results.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n ICCIVC was more effective and safer than other anti-VEGF regimens for NVG. Simultaneous intravitreal and intracameral injection was found to be the best route of administration, and conbercept was found to be the superior drug selection when compared with ranibizumab and bevacizumab.<\/jats:p>\n <\/jats:sec>\n \n PROSPERO registration number<\/jats:title>\n CRD42022309676.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-080103","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:05:37Z","timestamp":1709597137000},"page":"e080103","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Comparative efficacy and safety of different anti-VEGF agents combined with different delivery methods for neovascular glaucoma: a systematic review and Bayesian network meta-analysis"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7180-1986","authenticated-orcid":false,"given":"Jiaqi","family":"Wang","sequence":"first","affiliation":[{"name":"Shaanxi Eye Hospital, Xi\u2019an People\u2019s Hospital (Xi\u2019an Fourth Hospital), Affiliated People\u2019s Hospital of Northwest University, Xi'an, Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2546-5194","authenticated-orcid":false,"given":"Yi-Ming","family":"Guo","sequence":"additional","affiliation":[{"name":"Shaanxi Eye Hospital, Xi\u2019an People\u2019s Hospital (Xi\u2019an Fourth Hospital), Affiliated People\u2019s Hospital of Northwest University, Xi'an, Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhan","family":"Wei","sequence":"additional","affiliation":[{"name":"Shaanxi Eye Hospital, Xi\u2019an People\u2019s Hospital (Xi\u2019an Fourth Hospital), Affiliated People\u2019s Hospital of Northwest University, Xi'an, Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Min","sequence":"additional","affiliation":[{"name":"Shaanxi Eye Hospital, Xi\u2019an People\u2019s Hospital (Xi\u2019an Fourth Hospital), Affiliated People\u2019s Hospital of Northwest University, Xi'an, Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Ye","sequence":"additional","affiliation":[{"name":"Shaanxi Eye Hospital, Xi\u2019an People\u2019s Hospital (Xi\u2019an Fourth Hospital), Affiliated People\u2019s Hospital of Northwest University, Xi'an, Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"2025121220305264000_14.3.e080103.1","article-title":"Anti-vascular endothelial growth factor for neovascular glaucoma","volume":"2","author":"Simha","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121220305264000_14.3.e080103.2","doi-asserted-by":"publisher","DOI":"10.1080\/08820530902800801"},{"key":"2025121220305264000_14.3.e080103.3","first-page":"12","article-title":"A review of neovascular glaucoma: etiology, pathogenesis, diagnosis, and treatment","volume":"58","author":"Urbonavi\u010di\u016bt\u0117","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"2025121220305264000_14.3.e080103.4","doi-asserted-by":"crossref","first-page":"101137","DOI":"10.1016\/j.disamonth.2021.101137","article-title":"Neovascular glaucoma","volume":"67","author":"Mannina","year":"2021","journal-title":"Dis Mon"},{"key":"2025121220305264000_14.3.e080103.5","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317112"},{"key":"2025121220305264000_14.3.e080103.6","article-title":"Anti\u2010Vascular endothelial growth factor for neovascular age\u2010related macular degeneration","volume":"8","author":"Solomon","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121220305264000_14.3.e080103.7","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e3282f0ca54"},{"key":"2025121220305264000_14.3.e080103.8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.18240\/ijo.2021.03.20","article-title":"Intracameral anti-VEGF injection for advanced neovascular glaucoma after vitrectomy with silicone oil tamponade","volume":"14","author":"Bai","year":"2021","journal-title":"Int J Ophthalmol"},{"key":"2025121220305264000_14.3.e080103.9","first-page":"113","article-title":"The efficacy and safety of intravitreal conbercept combined with mitomycin C augmented trabeculectomy for treating neovascular glaucoma","volume":"29","author":"Jiang","year":"2020","journal-title":"Discov Med"},{"key":"2025121220305264000_14.3.e080103.10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00417-022-05785-5","article-title":"A systematic review and meta-analysis of randomised controlled trials in the management of neovascular glaucoma: absence of consensus and variability in practice","volume":"261","author":"Ramji","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2025121220305264000_14.3.e080103.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.06.066"},{"key":"2025121220305264000_14.3.e080103.12","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e3180457c47"},{"key":"2025121220305264000_14.3.e080103.13","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.145714"},{"key":"2025121220305264000_14.3.e080103.14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/jop.2008.0088","article-title":"Simultaneous intravitreal and Intracameral injection of bevacizumab (avastin) in neovascular glaucoma","volume":"25","author":"Yuzbasioglu","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"key":"2025121220305264000_14.3.e080103.15","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1007\/s12325-020-01580-y","article-title":"Efficacy and safety of intravitreal aflibercept injection in Japanese patients with neovascular glaucoma: outcomes from the VENERA study","volume":"38","author":"Inatani","year":"2021","journal-title":"Adv Ther"},{"key":"2025121220305264000_14.3.e080103.16","first-page":"837","article-title":"Intravitreal bevacizumab and ahmed glaucoma valve implantation in patients with neovascular glaucoma","volume":"7","author":"Zhang","year":"2014","journal-title":"Int J Ophthalmol"},{"key":"2025121220305264000_14.3.e080103.17","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007221","article-title":"Management of neovascular glaucoma with intravitreal ranibizumab, panretinal photocoagulation, and subsequent 5-fluorouracil augmented trabeculectomy: a case report","volume":"96","author":"Zhao","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2025121220305264000_14.3.e080103.18","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"2025121220305264000_14.3.e080103.19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025121220305264000_14.3.e080103.20","unstructured":"Dias S , Welton NJ , Sutton AJ , et al . NICE decision support unit technical support documents [Copyright \u00a9 2014 National Institute for Health and Clinical Excellence, unless otherwise stated. All rights reserved]. In: NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. London: National Institute for Health and Care Excellence (NICE), 2014."},{"key":"2025121220305264000_14.3.e080103.21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2105\/AJPH.2020.305609","article-title":"Cochrane handbook for systematic reviews of interventions","volume":"110","author":"Nasser","year":"2020","journal-title":"Am J Public Health"},{"key":"2025121220305264000_14.3.e080103.22","unstructured":"Dias S , Sutton AJ , Welton NJ , et al . NICE decision support unit technical support documents [Copyright \u00a9 2012 National Institute for Health and Clinical Excellence, unless otherwise stated. All rights reserved]. In: Heterogeneity: Subgroups, Meta-Regression, Bias And Bias-Adjustment. London: National Institute for Health and Care Excellence (NICE), 2012."},{"key":"2025121220305264000_14.3.e080103.23","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1044"},{"key":"2025121220305264000_14.3.e080103.24","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.jval.2015.10.002","article-title":"Using generalized linear mixed models to evaluate inconsistency within a network meta-analysis","volume":"18","author":"Tu","year":"2015","journal-title":"Value Health"},{"key":"2025121220305264000_14.3.e080103.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.07.005"},{"key":"2025121220305264000_14.3.e080103.26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"2025121220305264000_14.3.e080103.27","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-2-201307160-00008"},{"key":"2025121220305264000_14.3.e080103.28","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f6008","article-title":"Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis","volume":"347","author":"Wu","year":"2013","journal-title":"BMJ"},{"key":"2025121220305264000_14.3.e080103.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7304.101"},{"key":"2025121220305264000_14.3.e080103.30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"Cinema: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"2025121220305264000_14.3.e080103.31","first-page":"759","article-title":"The application of Conbercept in the treatment of diabetic retinopathy with stage I and II Neovascular glaucoma","volume":"36","author":"Jianyuan","year":"2020","journal-title":"Chin J Ocul Fundus Dis"},{"key":"2025121220305264000_14.3.e080103.32","first-page":"80","article-title":"Therapeutic effects of Ranibizumab combined with Trabeculectomy and Panretinal Photocoagulation for Neovascular glaucoma","volume":"38","author":"Feng-Yan","year":"2018","journal-title":"Recent Advances in Ophthalmology"},{"key":"2025121220305264000_14.3.e080103.33","first-page":"1855","article-title":"Anti-VEGF medicine with PRP for Neovascular glaucoma","volume":"18","author":"Deng","year":"2018","journal-title":"Guoji Yanke Zazhi (Int Eye Sci)"},{"key":"2025121220305264000_14.3.e080103.34","doi-asserted-by":"crossref","first-page":"563","DOI":"10.5301\/ejo.5000089","article-title":"Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab","volume":"22","author":"Wittstr\u00f6m","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"2025121220305264000_14.3.e080103.35","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12493"},{"key":"2025121220305264000_14.3.e080103.36","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.766032","article-title":"The optimization of an anti-VEGF therapeutic regimen for neovascular glaucoma","volume":"8","author":"Bai","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025121220305264000_14.3.e080103.37","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/IJG.0b013e318259aec4","article-title":"Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by ahmed valve implantation in neovascular glaucoma","volume":"22","author":"Mahdy","year":"2013","journal-title":"J Glaucoma"},{"key":"2025121220305264000_14.3.e080103.38","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e3181997211"},{"key":"2025121220305264000_14.3.e080103.39","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s10792-021-01846-6","article-title":"Comparison of conbercept and ranibizumab combined mitomycin C-augmented trabeculectomy for neovascular glaucoma","volume":"41","author":"Guo","year":"2021","journal-title":"Int Ophthalmol"},{"key":"2025121220305264000_14.3.e080103.40","first-page":"293","article-title":"Comparison on the efficacy of the two drugs combined with Trabeculectomy for the treatment of Neovascular glaucoma","volume":"39","author":"Guo Fei","year":"2017","journal-title":"Chinese Journal of Ocular Trauma and Occupational Eye Disease"},{"key":"2025121220305264000_14.3.e080103.41","first-page":"44","article-title":"Conbercept intravitreal injection combined with compound Trabeculectomy and Pan-retinal Photocoagulation for Neovascular glaucoma","volume":"5","author":"JX-d","year":"2020","journal-title":"Systems Medicine"},{"key":"2025121220305264000_14.3.e080103.42","first-page":"1380","article-title":"Clinical observation of intravitreal injection of Ranibizumab combined with argon laser therapy in the treatment of ischemic Neovascular glaucoma","volume":"29","author":"Wei","year":"2018","journal-title":"China Pharmacy"},{"key":"2025121220305264000_14.3.e080103.43","first-page":"99","article-title":"Effect of intravitreal injection of Ranibizumab in the treatment of Neovascular glaucoma and its influence on visual acuity and intraocular pressure","volume":"3","author":"Wen-jing","year":"2018","journal-title":"Clinical Research and Practice"},{"key":"2025121220305264000_14.3.e080103.44","first-page":"125","article-title":"Intravitreal injection of Lucentis combined with Trabeculectomy for Neovascular glaucoma","volume":"37","author":"Dajiang","year":"2015","journal-title":"Chinese Journal of Ocular Trauma and Occupational Eye Disease"},{"key":"2025121220305264000_14.3.e080103.45","first-page":"85","article-title":"Efficacy of intravitreal injection of Ranibizumab combined with Scleral Ciliary body Photocoagulation in the treatment of Neovascular glaucoma","volume":"29","author":"Zhen-zhen Yan","year":"2019","journal-title":"China Journal of Modern Medicine"},{"key":"2025121220305264000_14.3.e080103.46","first-page":"85","article-title":"GAO Yang: value of vitreous and anterior chamber injection of Conbercept in treatment of Neovascular glaucoma","volume":"29","author":"Zhang Jian","year":"2019","journal-title":"China Journal of Chinese Ophthalmology"},{"key":"2025121220305264000_14.3.e080103.47","first-page":"1137","article-title":"Intravitreal injection of Ranibizumab combined with Trabeculectomy and Panretinal Photocoagulation for Neovascular glaucoma","volume":"33","author":"Fang-fang","year":"2017","journal-title":"The Journal of Practical Medicine"},{"key":"2025121220305264000_14.3.e080103.48","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-051794","article-title":"Comparisons of the short-term effectiveness and safety of surgical treatment for neovascular glaucoma: a systematic review and network meta-analysis","volume":"12","author":"Lin","year":"2022","journal-title":"BMJ Open"},{"key":"2025121220305264000_14.3.e080103.49","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009897","article-title":"Effectiveness of multiple therapeutic strategies in neovascular glaucoma patients: a PRISMA-compliant network meta-analysis","volume":"97","author":"Dong","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2025121220305264000_14.3.e080103.50","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027326","article-title":"Effect of anti-vascular endothelial growth factor on the surgical outcome of neovascular glaucoma: an overview and meta-analysis","volume":"100","author":"Hwang","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2025121220305264000_14.3.e080103.51","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/IAE.0000000000000900","article-title":"Intravitreal conbercept (Kh902) for surgical treatment of severe proliferative diabetic retinopathy","volume":"36","author":"Su","year":"2016","journal-title":"RETINA"},{"key":"2025121220305264000_14.3.e080103.52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5005\/jp-journals-10008-1200","article-title":"Study of the effect of injection bevacizumab through various routes in neovascular glaucoma","volume":"10","author":"Bhagat","year":"2016","journal-title":"J Curr Glaucoma Pract"},{"key":"2025121220305264000_14.3.e080103.53","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2415-14-55","article-title":"Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: a retrospective analysis","volume":"14","author":"Nakatake","year":"2014","journal-title":"BMC Ophthalmol"},{"key":"2025121220305264000_14.3.e080103.54","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00417-010-1406-x","article-title":"Effect of intravitreal bevacizumab on Iris vessels in neovascular glaucoma patients","volume":"248","author":"Sugimoto","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2025121220305264000_14.3.e080103.55","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000230425.31296.3b"},{"key":"2025121220305264000_14.3.e080103.56","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200603000-00016"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-080103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:31:06Z","timestamp":1765600266000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-080103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":56,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,4]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/bmjopen-2023-080103"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-080103","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}